• The maximum percent increase in FEV1 (%) from baseline within the scheduled first 30 minutes of spirometric evaluations post dose [ Time Frame: Study Days 1 and 2 ] [ Designated as safety issue: No ]
• The maximum percent increase in FEV1 from baseline over 2 hours [ Time Frame: Study days 1 and 2 ] [ Designated as safety issue: No ]
• The area-under-the-effect curve of change in FEV1 from test-day baseline versus time [ Time Frame: Study days 1 and 2 ] [ Designated as safety issue: No ]

This is a research study designed to compare the single-dose effectiveness of albuterol-HFA-BAI (breath activated inhaler) and albuterol-HFA-MDI (metered dose inhaler) in asthmatics with poor inhaler coordinating abilities. Patients must be 7 to 70 years of age to participate in this study.

• Drug: Albuterol-HFA-MDI
• Drug: Albuterol-HFA-BAI

• Active Comparator: Albuterol Hydrofluoroalkane (HFA) Breath-Actuated Inhaler (BAI)
• Active Comparator: Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Inclusion Criteria:

• Male or females aged 7-70 years old
• Asthma of a minimum of 6 months duration
• Patients who demonstrate poor inhalation/actuation coordination when evaluated with the AIM -Aerosol Inhalation Monitor.
• Reversible bronchoconstriction of >12% increase in FEV1 with a cumulative dose of 450 mcg of albuterol
• The reversibility (FEV1) of <70% following administration of the initial 90 mcg of albuterol
• Ability to perform spirometry reproducibly
• Ability to self-perform PEF determinations and report scores on diaries
• Can tolerate withdrawal of applicable medications at screening
• Otherwise healthy individuals
• Non-smokers for at least two years

Exclusion Criteria:

• Allergy or sensitivity to albuterol
• Exposure to investigational drugs within 30 days prior to the screening visit
• Continuous treatment with Beta-blockers, MAO inhibitors, tricyclic antidepressants, and/or systemic corticosteroids
• Treated with oral or injectable corticosteroids within the six weeks prior to the screening visit
• Unstable dose regimen of any required antileukotrienes, inhaled corticosteroids and/or inhaled cromolyn and/or nedocromil
• Inability to tolerate or unwillingness to comply with required washout periods for all applicable medications
• Hospitalization for acute exacerbation of asthma more than twice in past year
• Treatment in an emergency room or hospitalization for asthmatic symptoms within three months prior to the screening visit
• An upper respiratory tract infection and/or sinusitis associated with exacerbation of asthma that is unresolved three weeks prior to the screening visit
• History and/or presence of any clinically significant non-asthmatic acute or chronic disease
• Known or suspected substance abuse
• Previous enrollment in an IVAX Research-sponsored Albuterol HFA asthma study
• Other criteria apply